Abstract
During development, inflammation or tissue injury, macrophages may successively engulf and process multiple apoptotic corpses via efferocytosis to achieve tissue homeostasis1. How macrophages may rapidly adapt their transcription to achieve continuous corpse uptake is incompletely understood. Transcriptional pause/release is an evolutionarily conserved mechanism, in which RNA polymerase (Pol) II initiates transcription for 20–60 nucleotides, is paused for minutes to hours and is then released to make full-length mRNA2. Here we show that macrophages, within minutes of corpse encounter, use transcriptional pause/release to unleash a rapid transcriptional response. For human and mouse macrophages, the Pol II pause/release was required for continuous efferocytosis in vitro and in vivo. Interestingly, blocking Pol II pause/release did not impede Fc receptor-mediated phagocytosis, yeast uptake or bacterial phagocytosis. Integration of data from three genomic approaches—precision nuclear run-on sequencing, RNA sequencing, and assay for transposase-accessible chromatin using sequencing (ATAC-seq)—on efferocytic macrophages at different time points revealed that Pol II pause/release controls expression of select transcription factors and downstream target genes. Mechanistic studies on transcription factor EGR3, prominently regulated by pause/release, uncovered EGR3-related reprogramming of other macrophage genes involved in cytoskeleton and corpse processing. Using lysosomal probes and a new genetic fluorescent reporter, we identify a role for pause/release in phagosome acidification during efferocytosis. Furthermore, microglia from egr3-deficient zebrafish embryos displayed reduced phagocytosis of apoptotic neurons and fewer maturing phagosomes, supporting defective corpse processing. Collectively, these data indicate that macrophages use Pol II pause/release as a mechanism to rapidly alter their transcriptional programs for efficient processing of the ingested apoptotic corpses and for successive efferocytosis.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
All raw and processed sequencing data generated in this study have been deposited as SuperSeries in the NCBI Gene Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo/) under accession number GSE253578. This SuperSeries comprises the following SubSeries: GSE253574 (ATAC-seq), GSE253576 (PRO-seq) and GSE25377 (RNA-seq). Publicly available datasets were used in this study: MSigDB resource: https://www.gsea-msigdb.org/gsea/msigdb/, UCSC Genome Browser annotation track database: https://genome.ucsc.edu/cgi-bin/hgTables, Jaspar database: https://jaspar.elixir.no and ENSEMBL: https://useast.ensembl.org/index.html. Gating strategy for efferocytosis (Supplementary Fig. 1) and raw, uncropped images of western blots (Supplementary Figs. 2 and 3) are provided in the Supplementary Information. Source data are provided with this paper.
Code availability
Custom codes used in this stud: for ATAC-seq, https://github.com/JetBrains-Research/chipseq-smk-pipeline; for PRO-seq https://github.com/AdelmanLab/NIH_scripts, https://github.com/lh3/seqtk and https://github.com/AdelmanLab/GetGeneAnnotation_GGA.
References
Morioka, S., Maueröder, C. & Ravichandran, K. S. Living on the edge: efferocytosis at the interface of homeostasis and pathology. Immunity 50, 1149–1162 (2019).
Muse, G. W. et al. RNA polymerase is poised for activation across the genome. Nat. Genet. 39, 1507–1511 (2007).
Chawla, A. et al. A PPARy-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 7, 161–171 (2001).
Czimmerer, Z. & Nagy, L. Epigenomic regulation of macrophage polarization: where do the nuclear receptors belong? Immunol. Rev. 317, 152–165 (2023).
Boada-Romero, E., Martinez, J., Heckmann, B. L. & Green, D. R. The clearance of dead cells by efferocytosis. Nat. Rev. Mol. Cell Biol. 21, 398–414 (2020).
Morioka, S. et al. Chimeric efferocytic receptors improve apoptotic cell clearance and alleviate inflammation. Cell 185, 4887–4903.e4817 (2022).
Yurdagul, A. et al. Macrophage metabolism of apoptotic cell-derived arginine promotes continual efferocytosis and resolution of injury. Cell Metab. 31, 518–533.e510 (2020).
Core, L. J., Waterfall, J. J. & Lis, J. T. Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science 322, 1845–1848 (2008).
Gressel, S., Schwalb, B. & Cramer, P. The pause-initiation limit restricts transcription activation in human cells. Nat. Commun. 10, 3603 (2019).
Shao, W. & Zeitlinger, J. Paused RNA polymerase II inhibits new transcriptional initiation. Nat. Genet. 49, 1045–1051 (2017).
Abuhashem, A., Garg, V. & Hadjantonakis, A.-K. RNA polymerase II pausing in development: orchestrating transcription. Open Biol. 12, 210220 (2022).
Yu, L. et al. Negative elongation factor complex enables macrophage inflammatory responses by controlling anti-inflammatory gene expression. Nat. Commun. 11, 2286 (2020).
Yamaguchi, Y., Inukai, N., Narita, T., Wada, T. & Handa, H. Evidence that negative elongation factor represses transcription elongation through binding to a DRB sensitivity-inducing factor/RNA polymerase II complex and RNA. Mol. Cell. Biol. 22, 2918–2927 (2002).
Wei, P., Garber, M. E., Fang, S. M., Fischer, W. H. & Jones, K. A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92, 451–462 (1998).
Fujinaga, K. et al. Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. Mol. Cell. Biol. 24, 787–795 (2004).
Kim, J. B. & Sharp, P. A. Positive transcription elongation factor B phosphorylates hSPT5 and RNA polymerase II carboxyl-terminal domain independently of cyclin-dependent kinase-activating kinase. J. Biol. Chem. 276, 12317–12323 (2001).
Henriques, T. et al. Stable pausing by RNA polymerase II provides an opportunity to target and integrate regulatory signals. Mol. Cell 52, 517–528 (2013).
Buckley, M. S., Kwak, H., Zipfel, W. R. & Lis, J. T. Kinetics of promoter Pol II on Hsp70 reveal stable pausing and key insights into its regulation. Genes Dev. 28, 14–19 (2014).
Lavin, Y. et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159, 1312–1326 (2014).
Boettiger, A. N. & Levine, M. Synchronous and stochastic patterns of gene activation in the Drosophila embryo. Science 325, 471–473 (2009).
Saha, R. N. et al. Rapid activity-induced transcription of Arc and other IEGs relies on poised RNA polymerase II. Nat. Neurosci. 14, 848–856 (2011).
Rougvie, A. E. & Lis, J. T. The RNA polymerase II molecule at the 5’ end of the uninduced hsp70 gene of D. melanogaster is transcriptionally engaged. Cell 54, 795–804 (1988).
Mahat, D. B., Salamanca, H. H., Duarte, F. M., Danko, C. G. & Lis, J. T. Mammalian heat shock response and mechanisms underlying its genome-wide transcriptional regulation. Mol. Cell 62, 63–78 (2016).
Kwak, H., Fuda, N. J., Core, L. J. & Lis, J. T. Precise maps of RNA polymerase reveal how promoters direct initiation and pausing. Science 339, 950–953 (2013).
Lücking, U. et al. Identification of atuveciclib (BAY 1143572), the first highly selective, clinical PTEFb/CDK9 inhibitor for the treatment of cancer. ChemMedChem 12, 1776–1793 (2017).
Jonkers, I., Kwak, H. & Lis, J. T. Genome-wide dynamics of Pol II elongation and its interplay with promoter proximal pausing, chromatin, and exons. eLife 3, e02407 (2014).
Liang, K. et al. Targeting processive transcription elongation via SEC disruption for MYC-induced cancer therapy. Cell 175, 766–779.e717 (2018).
DeBerardine, M., Booth, G. T., Versluis, P. P. & Lis, J. T. The NELF pausing checkpoint mediates the functional divergence of Cdk9. Nat. Commun. 14, 2762 (2023).
Aoi, Y. et al. SPT5 stabilization of promoter-proximal RNA polymerase II. Mol. Cell 81, 4413–4424.e4415 (2021).
Robb, C. M. et al. Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chem. Commun. 53, 7577–7580 (2017).
Vos, S. M., Farnung, L., Urlaub, H. & Cramer, P. Structure of paused transcription complex Pol II–DSIF–NELF. Nature 560, 601–606 (2018).
Alexandra, G. C. et al. Evolution of promoter-proximal pausing enabled a new layer of transcription control. Preprint at bioRxiv https://doi.org/10.1101/2023.02.19.529146 (2023).
Gilchrist, D. A. et al. Pausing of RNA polymerase II disrupts DNA-Specified nucleosome organization to enable precise gene regulation. Cell 143, 540–551 (2010).
Raymond, M. H. et al. Live cell tracking of macrophage efferocytosis during Drosophila embryo development in vivo. Science 375, 1182–1187 (2022).
Wang, Y. et al. Mitochondrial fission promotes the continued clearance of apoptotic cells by macrophages. Cell 171, 331–345.e322 (2017).
Lara Ordóñez, A. J., Fasiczka, R., Naaldijk, Y. & Hilfiker, S. Rab GTPases in Parkinson’s disease: a primer. Essays Biochem. 65, 961–974 (2021).
Proto, J. D. et al. Regulatory T cells promote macrophage efferocytosis during inflammation resolution. Immunity 49, 666–677.e666 (2018).
Maschalidi, S. et al. Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes. Nature 606, 776–784 (2022).
Gerlach, B. D. et al. Efferocytosis induces macrophage proliferation to help resolve tissue injury. Cell Metab. 33, 2445–2463.e2448 (2021).
Meriwether, D. et al. Macrophage COX2 mediates efferocytosis, resolution reprogramming, and intestinal epithelial repair. Cell Mol. Gastroenterol. Hepatol. 13, 1095–1120 (2022).
Park, D. et al. BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature 450, 430–434 (2007).
Brahma, S. & Henikoff, S. The BAF chromatin remodeler synergizes with RNA polymerase II and transcription factors to evict nucleosomes. Nat. Genet. 56, 100–111 (2023).
Lambert, S. A. et al. The human transcription factors. Cell 172, 650–665 (2018).
Svaren, J. et al. NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli. Mol. Cell. Biol. 16, 3545–3553 (1996).
Swirnoff, A. H. et al. Nab1, a corepressor of NGFI-A (Egr-1), contains an active transcriptional repression domain. Mol. Cell. Biol. 18, 512–524 (1998).
Canchi, S. et al. Integrating gene and protein expression reveals perturbed functional networks in Alzheimer’s disease. Cell Rep. 28, 1103–1116.e1104 (2019).
Tourtellotte, W. & Milbrandt, J. Sensory ataxia and muscle spindle agenesis in mice lacking the transcription factor Egr3. Nat. Genet. 20, 87–91 (1998).
Casano, A. M., Albert, M. & Peri, F. Developmental apoptosis mediates entry and positioning of microglia in the zebrafish brain. Cell Rep. 16, 897–906 (2016).
Faronato, M. et al. DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation. Oncotarget 6, 22467–22479 (2015).
Wang, G. G. et al. Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. Nat. Methods 3, 287–293 (2006).
Corces, M. R. et al. An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat. Methods 14, 959–962 (2017).
Köster, J. & Rahmann, S. Snakemake—a scalable bioinformatics workflow engine. Bioinformatics 28, 2520–2522 (2012).
Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).
Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).
Ramírez, F., Dündar, F., Diehl, S., Grüning, B. A. & Manke, T. deepTools: a flexible platform for exploring deep-sequencing data. Nucleic Acids Res. 42, W187–W191 (2014).
Shpynov, O., Dievskii, A., Chernyatchik, R., Tsurinov, P. & Artyomov, M. N. Semi-supervised peak calling with SPAN and JBR genome browser. Bioinformatics 37, 4235–4237 (2021).
Zhang, Y. et al. Model-based Analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842 (2010).
Ross-Innes, C. S. et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389–393 (2012).
Zhu, L. J. et al. ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC Bioinform. 11, 237 (2010).
Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576–589 (2010).
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
Danecek, P. et al. Twelve years of SAMtools and BCFtools. GigaScience 10, giab008 (2021).
Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Julius, J. et al. A rapid, sensitive, scalable method for Precision Run-On sequencing (PRO-seq). Preprint at bioRxiv https://doi.org/10.1101/2020.05.18.102277 (2020).
Reimer, K. A., Mimoso, C. A., Adelman, K. & Neugebauer, K. M. Co-transcriptional splicing regulates 3′ end cleavage during mammalian erythropoiesis. Mol. Cell 81, 998–1012.e1017 (2021).
Smith, T., Heger, A. & Sudbery, I. UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy. Genome Res. 27, 491–499 (2017).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739–1740 (2011).
Nüsslein-Volhard, C. The zebrafish issue of Development. Development 139, 4099–4103 (2012).
Santos, D., Luzio, A. & Coimbra, A. M. Zebrafish sex differentiation and gonad development: a review on the impact of environmental factors. Aquat. Toxicol. 191, 141–163 (2017).
Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B. & Schilling, T. F. Stages of embryonic development of the zebrafish. Dev. Dyn. 203, 253–310 (1995).
Peri, F. & Nüsslein-Volhard, C. Live imaging of neuronal degradation by microglia reveals a role for v0-ATPase a1 in phagosomal fusion in vivo. Cell 133, 916–927 (2008).
Gray, C. et al. Simultaneous intravital imaging of macrophage and neutrophil behaviour during inflammation using a novel transgenic zebrafish. Thromb. and Haemost. 105, 811–819 (2011).
Villani, A. et al. Clearance by microglia depends on packaging of phagosomes into a unique cellular compartment. Dev. Cell 49, 77–88.e77 (2019).
Möller, K. et al. A role for the centrosome in regulating the rate of neuronal efferocytosis by microglia in vivo. eLife 11, e82094 (2022).
Shiau, C. E., Kaufman, Z., Meireles, A. M. & Talbot, W. S. Differential requirement for irf8 in formation of embryonic and adult macrophages in zebrafish. PLoS ONE 10, e0117513 (2015).
Wu, X., Shen, W., Zhang, B. & Meng, A. The genetic program of oocytes can be modified in vivo in the zebrafish ovary. J. Mol. Cell. Biol. 10, 479–493 (2018).
Kenyon, A. et al. Active nuclear transcriptome analysis reveals inflammasome-dependent mechanism for early neutrophil response to Mycobacterium marinum. Sci. Rep. 7, 6505 (2017).
Acknowledgements
We thank members of Ravichandran laboratory for input and critical reading of the manuscript; the Centre for Microscopy and Image Analysis, University of Zürich, for the Olympus IXplore SpinSR10 and the Leica SP8 inverse confocal laser scanning microscopes; and the Nascent Transcriptomics Core at Harvard Medical School for generating PRO-seq libraries and for assistance with data analysis. We thank the laboratory of Todd Fehniger for sourcing of human leukocytes from ImpactLife Blood Centers, and thank J. Milbrandt for providing Egr3-knockout mice. Schematics in Figs. 1a,d,e,g–j, 2a,d,g, 3a,c,f and 4a,d,h and Extended Data Figs. 3a,c,f, 4c, 5a and 6b,e,f were created using BioRender images as templates. T.T. was supported by a predoctoral fellowship from the American Heart Association (AHA 835593). K.S.R. was supported by NIAID (R01AI159551) and BJC Investigator Funds from the Washington University School of Medicine. S.K. was supported by an F31 fellowship from the NHLBI (1F31HL160134) and J.I.E. was supported by a fellowship from the NEI (EY031211). R.M.E. was supported by T32 Immunology Grant (T32AI007163). L.B. was supported by Emmanuel van der Schueren (EvdS) starter scholarship from Kom op tegen Kanker. E.B. and A.V. were supported by grants from the Swiss National Foundation grants (SNF310030_212794 and SNF31003A_182733).
Author information
Authors and Affiliations
Contributions
T.T. and K.S.R. designed all experiments and wrote the manuscript. T.T. performed most of the experiments. A.V., E.B. and F.P. assisted with the zebrafish experiments. S.R.G. assisted with the PRO-seq libraries. G.M.N. assisted with the PRO-seq analysis. O.S. and M.N.A. assisted with the ATAC-seq analysis. M.T. and P.Z. assisted with the RNA-seq analysis. G.C., S.K., R.M.E., J.S., Y.C., M.S., J.I.E. and L.B. assisted with various experiments. L.W.P. assisted with the generation of human PBMCs. M.R. assisted with the CharOFF construction.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature thanks Edward Thorp and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data figures and tables
Extended Data Fig. 1 Upregulated genes exhibit reduced pausing indices and pathway divergence during efferocytosis.
a, Gene Ontology pathway analysis (MSigDB) of upregulated and downregulated genes (determined by DESeq2, using the Wald test, padj<0.001) from the PRO-seq data at 45 min of efferocytosis (versus resting macrophages). b, Metagene plot of PRO-seq reads for the 331 genes upregulated in macrophages after 45 min efferocytosis (per Wald test) c, Heat map of PRO-seq signals around the proximal promoter region and gene body of the 331 genes upregulated in macrophages after 45 min efferocytosis. d, e, Cumulative distribution of pausing indices (from four independent experiments) of 331 upregulated genes (n-331) (d) and 105 randomly selected unchanged genes (e) as determined by DESeq2 and the Wald test (left). Pausing indices for each gene are compared between resting macrophages and macrophages after 45 min (top) or 90 min (bottom) of efferocytosis. Paired tow-tailed t-tests. ****p < 0.0001, ns: not significant. f, Upregulated genes (331) were divided into highly paused (PI > 4) and lowly paused genes (PI < 4), and pathway analysis performed via GSEA-MSigDB data base (https://www.gsea-msigdb.org/gsea/msigdb). In all figures, data are from four independent experimental replicates.
Extended Data Fig. 2 Pause/release effects on efferocytosis versus Fc receptor-mediated phagocytosis.
a, Immunoblotting showing CDK9, Ser2P and β-Actin protein levels in macrophages treated with either DMSO or flavopiridol (10 µM) for 30 min. n = 3 independent experiments. b, Macrophages treated with DMSO or CDK9 inhibitors were incubated with TAMRA (pH-insensitive)-stained apoptotic Jurkat cells for 30 min. c, CDK9, Ser2P and β-Actin levels in macrophages treated with PROTAC-CDK9 (20 µM) for indicated times (left) or NVP-2 (concentrations indicated) for 30 min (right). n = 1 experiment. d, Efferocytosis quantified in macrophages with concurrent CDK9 inhibitors and apoptotic cells addition. n = 4 (left) and n = 3 (right) independent experiments. Paired two-tailed t-test. e, Uptake of anti-CD90.2-opsonized thymocytes by macrophages treated with NVP-2 (10 µM) or THAL-SNS-032 (20 µM) for 30 min. f, Editing efficiency in CRISPR/Cas9-generated NELFB- and NELFCD-deficient macrophages. n = 1 experiment. g, Efferocytosis kinetics were measured by live cell imaging (Incucyte) using WT and NELF-deficient macrophages incubated with CypHer5E-stained apoptotic Jurkat cells. Cytochalasin D was used as a control. Data are mean ± SEM. n = 4 independent experiments. Area under curve analysis and then unpaired two-tailed t-test with Welch’s correction. h, i, Continuous efferocytosis by human macrophages (left, n = 4 and right, n = 3 human donors of PBMCs; paired two-tailed t-test) (h) and mouse macrophages (i) treated with DMSO or CDK9 inhibitors. j, Second corpse uptake by mouse macrophages treated with CDK9 inhibitors and fed CypHer5E- and TAMRA-stained apoptotic Jurkat cells at a ratio of 1:1:1 apoptotic cell to phagocyte for 30 min. Double-positive macrophages have engulfed at least two corpses. n = 7 (left) and n = 6 (right) independent experiments. Paired two-tailed t-test. k, l, Continuous uptake of opsonized thymocytes in macrophages treated with DMSO or PROTAC-CDK9. d, g, h, j, Some of control samples were concurrently used in parallel experiments. b, e, i, l, In box and whiskers graphs (the center line denotes median, box edges encompass 25th to 75th percentiles, min to max points), dots show values from four independent experiments, unpaired two-tailed t-test. In all figures, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.001, ns: not significant. Schematics in b,f,i–k created with BioRender.com.
Extended Data Fig. 3 Acidification and specific gene expression patterns during efferocytosis.
a, Continuous efferocytosis of CSFE+ (first round) and TAMRA+ (second round) apoptotic cells by macrophages pre-treated for 30 min with DMSO or bafilomycin A1. n = 4 independent experiments, paired two-tailed t-test. b, Relative expression (as determined by qPCR) of the indicated genes over time in macrophages during phagocytosis of synthetic beads. Data are mean ± SEM. c, PtdSer exposure was induced in RBCs using a calcium ionophore (A23187) and quantified by annexin V staining (left). The uptake of CypHer5E-stained PtdSer+ RBCs by mouse macrophages was assessed by flow cytometry (right) n = 4 independent experiments. Unpaired two-tailed t-test. d, Relative expression of EGR3 (as determined by qPCR) in human macrophages treated with DMSO or flavopiridol during efferocytosis. n:5 human donors of PBMCs; one-way ANOVA with Tukey’s multiple comparisons. a, c, d, In box and whiskers graphs, the center line denotes median, box edges encompass 25th to 75th percentiles, min to max points, and dots show independent data points. In all figures, *p < 0.05, **p < 0.01, ****p < 0.0001, ns: not significant. Schematics in a,c,d created with BioRender.com.
Extended Data Fig. 4 EGR3 upregulation via Pol II pause/release during efferocytosis.
a, Heat map (derived from RNA-seq analysis) depicting differentially upregulated transcription factors (Wald test and corrected for multiple testing using the Benjamini and Hochberg method) at 45 min efferocytosis. Genes were ranked by fold-change. Data are from four independent experimental replicates. b, PRO-seq tracks (left) and relative pausing index (right) for Egr3 in resting macrophages and during efferocytosis. n = 4 independent experimental replicates. c, Schematic depicting ATAC-seq experiment in which mouse macrophages were fed apoptotic human Jurkat cells for 15 min, 30 min or 45 min of efferocytosis. n = 4 independent experimental replicates. d, Tracks of ATAC-seq showing chromatin accessibility in the promoter region of Egr3 in the resting state and during efferocytosis. Data derived from four independent experimental replicates. e, Relative expression of Egr3 in macrophages (as determined by qPCR) following Egr3 knockdown via shRNA (left) and Egr3 overexpression via retroviral vector (right). Data are presented as mean ± SEM. n = 3 independent experiments. f, Uptake of CypHer5E-stained apoptotic cells by wild type and Egr3-OE macrophages treated with either DMSO or flavopiridol. Two-way ANOVA with Tukey’s multiple comparisons. *p < 0.05 g, Fc receptor-mediated phagocytosis of CSFE-stained opsonized thymocytes by wild type, Egr3-deficient and Egr3-OE macrophages was assessed by flow cytometry after 30 min. Thymocytes opsonized with IgG was used as a control. One-way ANOVA with Tukey’s multiple comparisons. ns: non-significant. (f, g) Box and whiskers graphs (the center line denotes median, box edges encompass 25th to 75th percentiles, min to max points), and dots show values from four independent experiments. Schematics in c created with BioRender.com.
Extended Data Fig. 5 egr3-deficient microglia in Zebrafish development exhibits impaired efferocytic capacity.
a, Schematic depicting the genome editing approach in zebrafish embryos (see method section for details). b, Percentage of injected embryos with confirmed deletion in exon 2 of egr3 across six independent experiments. CRISPANTs embryos (296 bp deletion) = 84.49%. Data are presented as mean ± s.d. N = 6 and 109 embryos analyzed. c, Immunoblotting (left) and quantification (right) of egr3 protein in control versus egr3 CRISPANTs embryos. n = 1 experiment. d, Representative dorsal images of non-injected irf8st95/st95 zebrafish embryo brain after Acridine Orange (AO) staining for apoptotic cells (top) and its segmentation (bottom). Quantification (right) of the basal levels of apoptosis in the optic tecta (OT) of non-injected irf8st95/st95 controls (N = 26) and egr3 CRISPANT (N = 23) embryos using Imaris automatic spot detection. Box and whiskers graphs (the center line denotes median, box edges encompass 25th to 75th percentiles, min to max points), unpaired two-tailed t-test. e, Representative images of a WT microglia at 3 days post fertilization (dpf) having the cytoplasm labelled in green (TgBAC(csf1ra:GAL4-VP16); Tg(UAS:nfsb-mCherry)) and freshly formed phagosomes labeled in magenta (Tg(UAS:mNeonGreen-Rab5)). The upper panel timepoint 1 (T1), in which the phagosome (arrowhead) is visible from the cell body (mCherry-green) but not yet in the Rab5 channel (mNeonGreen-magenta). T2 (4.5 min later) shows Rab5 recruitment to freshly formed phagosomes (arrowhead), indicating successful phagocytosis. Scale bar 10 µm. f, Quantification of phagocytic events (Rab5+ vesicles formed) in each microglia per hour counted. Violin plot, unpaired two-tailed t-test. g, Percentage of microglia having one or no successful phagocytic event (Rab5+ vesicles) per hour over the total. WT controls= 19.3%; egr3 CRISPANTs= 56.4%. e-g, T2 in WT control (N = 7 and n = 88) and egr3 CRISPANT (N = 7 and n = 101) where N=number of embryos and n=number of microglia cells quantified. h, Heat map of differential expression of EGR3-regulated genes that are associated with endosomal pathways. The Wald test corrected for multiple testing using the Benjamini and Hochberg method. padj<0.05. i, j, Knockdown efficiency of siRNAs targeting Dmxl2 and Elmo1. Unpaired two-tailed t-test. Three independent experiments, data are presented as mean ± SEM. k, Defective acidification in Dmxl2-deficient macrophages as shown by lysotracker staining during efferocytosis. n:3 independent experiments, paired two-tailed t-test. In all figures, *p < 0.05, **p < 0.01, ****p < 0.0001, ns: non-significant. Schematics in a created with BioRender.com.
Extended Data Fig. 6 The pre-corpse internalization stages of efferocytosis impact Pol II release.
a, b, Defective acidification in Egr3-deficient macrophages as shown by lysotracker staining during efferocytosis (a) and GFP quenching in macrophages engulfing CharOFF cells (b). a, Box and whiskers graphs (the center line denotes median, box edges encompass 25th to 75th percentiles, min to max points). n = 4, paired two-tailed t-test. b, n = 3; ratio paired two-tailed t-test. c, Relative expression level of Egr1 and Egr3 (as determined by qPCR) in DMSO (n = 4) and flavopiridol (n = 3)-treated macrophages incubated with medium alone, supernatant from live Jurkat cells, and supernatant from apoptotic Jurkat cells for 30 min. Data are presented as mean ± SEM. Unpaired two-tailed t-test. d, e, Relative expression of Egr1 (n = 7) and Egr3 (n = 5) in CytoD (actin polymerization inhibitor)-treated macrophages with and without apoptotic cells (d) and DMSO or BMS (pan-TAM inhibitor) during efferocytosis (e). Paired two-tailed t-test. f, Relative expression of Egr3 in macrophages treated with either IgG (antibody control) or Axl and MerTK (20 nM) activating antibodies for 30 min. n:3, unpaired two-tailed t-test. In all figures, data points represent individual values for ‘n’ biologically independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. Schematics in b,e,f created with BioRender.com.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Tufan, T., Comertpay, G., Villani, A. et al. Rapid unleashing of macrophage efferocytic capacity via transcriptional pause release. Nature 628, 408–415 (2024). https://doi.org/10.1038/s41586-024-07172-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41586-024-07172-y